Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-acetamido-3-mercapto-l-propionamide
2. N-acetylcysteinamide
1. 38520-57-9
2. (r)-2-acetamido-3-mercaptopropanamide
3. Acetylcysteine Amide
4. Nac Amide
5. N-acetyl-l-cysteinamide
6. Naca
7. Acetylcysteinamide
8. N-acetyl-l-cysteine Amide
9. N-acetyl Cysteine Amide
10. N-acetyl-cysteine-amide
11. N-acetylcysteinamide
12. Propanamide, 2-(acetylamino)-3-mercapto-, (2r)-
13. Mfcd01696115
14. 4n69717rkw
15. Propanamide, 2-(acetylamino)-3-mercapto-, (r)-
16. (2r)-2-acetamido-3-sulfanylpropanamide
17. (2r)-2-(acetylamino)-3-mercaptopropanamide;
18. Unii-4n69717rkw
19. N-acetylcysteine Amide [who-dd]
20. Ac-cys-nh2
21. (r)- 2-(acetylamino)-3-mercapto-propanamide
22. N-acetylcysteine Amide;(r)-2-acetamido-3-mercaptopropanamide
23. Schembl377413
24. Dtxsid30436398
25. Chebi:231847
26. Ujchizdeqzmodr-bypyzucnsa-n
27. Hms3886b05
28. S5804
29. Akos006373417
30. Db14480
31. Da-55966
32. N-acetylcysteine Amide, >=98% (hplc)
33. Hy-110256
34. Cs-0033121
35. Q15408428
| Molecular Weight | 162.21 g/mol |
|---|---|
| Molecular Formula | C5H10N2O2S |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 73.2 |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 149 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nacuity Pharmaceuticals Receives FDA Fast Track for NPI-001 in Retinitis Pigmentosa
Details : NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 21, 2025
Details:
NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Arctic Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2024
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Arctic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Arctic and Nacuity Announce EMA Approval to Initiate Trial of AT-001 for HCCAA
Details : NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2024
Details:
N-Acetylcysteine Amide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cystinosis.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and PD Study of NPI-001 and Cysteamine Bitartrate
Details : N-Acetylcysteine Amide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cystinosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Details:
NPI-001 is an oral, small molecule, proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH).
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2023
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NPI-001 is an oral, small molecule, proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2023
Details:
NPI-001 is a differentiated, purified, prescription-quality, GMP-grade N-acetylcysteine amide (NACA) being developed to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Arctic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Arctic Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : NPI-001 is a differentiated, purified, prescription-quality, GMP-grade N-acetylcysteine amide (NACA) being developed to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 13, 2022
Details:
Proceeds from the financing will be used to support the advancement of Nacuity’s clinical trials for NPI-001 and NPI-002 through proof of concept, as well as for general operations.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Foundation Fighting Blindness
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2022
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Foundation Fighting Blindness
Deal Size : $16.5 million
Deal Type : Series B Financing
Details : Proceeds from the financing will be used to support the advancement of Nacuity’s clinical trials for NPI-001 and NPI-002 through proof of concept, as well as for general operations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 15, 2022
Details:
Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.
Lead Product(s): N-Acetylcysteine Amide,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Nacuity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021
Lead Product(s) : N-Acetylcysteine Amide,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Nacuity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
20
PharmaCompass offers a list of N-Acetylcysteine Amide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right N-Acetylcysteine Amide manufacturer or N-Acetylcysteine Amide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred N-Acetylcysteine Amide manufacturer or N-Acetylcysteine Amide supplier.
PharmaCompass also assists you with knowing the N-Acetylcysteine Amide API Price utilized in the formulation of products. N-Acetylcysteine Amide API Price is not always fixed or binding as the N-Acetylcysteine Amide Price is obtained through a variety of data sources. The N-Acetylcysteine Amide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A N-Acetylcysteine Amide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of N-Acetylcysteine Amide, including repackagers and relabelers. The FDA regulates N-Acetylcysteine Amide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. N-Acetylcysteine Amide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A N-Acetylcysteine Amide supplier is an individual or a company that provides N-Acetylcysteine Amide active pharmaceutical ingredient (API) or N-Acetylcysteine Amide finished formulations upon request. The N-Acetylcysteine Amide suppliers may include N-Acetylcysteine Amide API manufacturers, exporters, distributors and traders.
N-Acetylcysteine Amide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of N-Acetylcysteine Amide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right N-Acetylcysteine Amide GMP manufacturer or N-Acetylcysteine Amide GMP API supplier for your needs.
A N-Acetylcysteine Amide CoA (Certificate of Analysis) is a formal document that attests to N-Acetylcysteine Amide's compliance with N-Acetylcysteine Amide specifications and serves as a tool for batch-level quality control.
N-Acetylcysteine Amide CoA mostly includes findings from lab analyses of a specific batch. For each N-Acetylcysteine Amide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
N-Acetylcysteine Amide may be tested according to a variety of international standards, such as European Pharmacopoeia (N-Acetylcysteine Amide EP), N-Acetylcysteine Amide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (N-Acetylcysteine Amide USP).
